ArticleJournal of ophthalmic inflammation and infection2025
Unilateral uveitis following adjuvanted Varicella-Zoster subunit vaccine in a patient with previously resolved Varicella Zoster acute retinal necrosis.
Article in Journal of ophthalmic inflammation and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report a case of intraocular inflammation following adjuvanted recombinant Varicella-Zoster subunit vaccine (RZV) in a patient with previously resolved VZV-related acute retinal necrosis (ARN).
methodsSingle case report. Multimodal imaging, including true-color fundus photography, spectral-domain (SD-OCT) and dye-based angiography, was used to evaluate the retinal alterations.
resultsA 73-year-old male, with past history of VZV-related acute retinal necrosis (ARN) developed unilateral cystoid macular edema and diffuse blood-retinal barrier (BRB) breakdown in the affected eye after receiving the second dose of RZV vaccine. A complete resolution of this complication was observed after a short course of systemic corticosteroids.
conclusionOur case suggests a possible pathogen-specific intraocular inflammatory reaction, resembling immune reconstitution uveitis (IRU), following RZV administration in a patient with previously resolved VZV-related ARN. While RZV remains safe, intraocular inflammation should be considered as a possible side effect in patients with previously resolved VZV uveitis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.